FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org January 8, 2009 (10.1056/NEJMe0809819)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mullighan, C. G. PubMed Citation

Acute lymphoblastic leukemia (ALL) with an immature B-cell immunophenotype (B-cell–progenitor ALL) is a common cancer in children and adolescents, and it also occurs in adults. Cure rates of B-cell–progenitor ALL among children are very high, but they are not as high among adults. Approximately one fifth of children with B-cell–progenitor ALL have recurring disease, which is difficult to treat. Thus, this form of ALL varies with respect to the potential for relapse and resistance to chemotherapy.

It is generally accepted that B-cell–progenitor ALL originates in B-cell–restricted progenitors that have accumulated critical genetic lesions. Cytogenetic studies of B-cell–progenitor ALL have revealed . . . [Full Text of this Article]

Source Information

From the Cutaneous Biology Research Center, Massachusetts General Hospital, and Harvard Medical School — both in Boston.

This article (10.1056/NEJMe0809819) was published at NEJM.org on January 8, 2009. It will appear in the January 29 issue of the Journal.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.